New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
07:02 EDTBIIB, ISISIsis receives $14M payment from Biogen with Phase 1 initiation
Isis Pharmaceuticals (ISIS) announced that it has initiated a Phase 1 study for ISIS-DMPK. Isis earned a $14M milestone payment from Biogen Idec (BIIB) associated with this achievement. ISIS-DMPK is designed to reduce the production of toxic dystrophia myotonica-protein kinase RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type.
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:40 EDTISISIsis Pharmaceuticals participates in a conference call with JPMorgan
Subscribe for More Information
May 21, 2015
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
May 15, 2015
09:31 EDTBIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use